Rockwell Medical (RMTI) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants Heather Hunter - Senior VP & Chief Corporate Affairs OfficerMark Strobeck - President & CEOJesse Neri - SVP & CFORaghuram Selvaraju - Managing Director, Healthcare Equity Research Conference Call Participants Jeremy Pearlman - Equity Analyst Operator Good morning, and welcome to Rockwell Medical's First Quarter twenty twenty five Results Conference Call and Webcast. Please note that this event is being recorded. At t ...

Advanced Micro Devices’ (AMD)  stock has risen 5% since surpassing its Q1 expectations on Tuesday, with the post-earnings rally gaining steam as President Trump boosted markets by announcing a new trade deal with the United Kingdom.With Trump revisiting the rhetoric of keeping chip manufacturing dominance in the U.S., it’s certainly a worthy topic of whether now is a good time to buy AMD stock for more upside. AMD’s Consistency Continues Stating AMD delivered an outstanding start to the year despite evolvin ...

To paraphrase Rockwell Automation’s NYSE: ROK CEO, Blake Moret, the company’s home-field advantage ideally positions it to benefit from onshoring U.S. manufacturing. Its manufacturing footprint is North American-centric, with more than 70% located within the continental US. The company is a leader in automation; its products are devices and tools to automate processes and increase efficiency, which businesses and industries need to manufacture domestically and succeed. Rockwell Automation TodayROKRockwell A ...

Core Insights - Kytopen Corp. and Bio-Techne Corporation have announced a partnership to enhance gene delivery solutions for advanced cell therapies, focusing on the integration of their respective technologies [1][5] - The collaboration aims to streamline workflows for genome engineering of immune cell therapies, expediting their clinical advancement and manufacturing [1][5] Company Overview - Kytopen is a leader in non-viral, continuous flow cellular engineering technologies, headquartered in Cambridge, Massachusetts, and is known for maximizing yields and delivering hundreds of billions of engineered cells rapidly [6] - Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [7] Technology Highlights - The TcBuster™ system allows for the simultaneous delivery of multiple genes with high editing efficiency, offering advantages over traditional lentivirus-based methods [2][5] - Flowfect® technology combines mechanical, electrical, and chemical forces to enhance transfection efficiency and cell health, enabling the processing of billions of cells in minutes [2][5] Collaboration Details - The partnership will leverage the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular engineering platform to create a non-viral gene-editing workflow suitable for various immune cell types [1][3] - Data from the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, showcasing the advancements made through this partnership [3][5]

Stratasys (SSYS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Future financial performance and our expectations for our business outlook. All statements that speak to future performance, events, expectations or results are forward looking statements. Actual results or trends could differ materially from our forecast. For risks that could cause actual results to be materially different from those set forth in forward looking statements, please refer to the risk factors discussed or referenced in S ...

今日盘后，国产晶圆代工领域的两大"明星企业"—— 中芯国际与华虹，其 2025 年第一季度财报正式亮相。 Q1中芯国际营业收入163.01亿元，同比增长29.4%，净利润13.56亿元，同比增长166.5%。净利润变动主要是由于晶圆销量上升、产品组合变化使营业收入 同比增加所致。 | 公司 | 数据类别 | 2024年01 | 2024年Q2 | 2024年03 | 2024年04 | 2025年01 | | --- | --- | --- | --- | --- | --- | --- | | 中心国际 | 营业收入 | 17.50亿美元 | 19.01亿美元 | 21.7亿美元 | 22.07美元 | 22.47 亿美元 | | | 营业收入同比 | 19.70% | 21.8% | 33.9% | 31.5% | l | | | 营业收入环比 | 4.30% | 8.6% | 14.2% | 1.7% | 1.8% | | | 归母净利润 | 0.72亿美元 | 1.65亿美元 | 1.47亿美元 | 1.08亿美元 | I | | | 归母净利润同比 | -68.90% | -59.1% | - 13 ...

Q1 2025 Results Speakers Dr. Yoav Zeif, CEO Eitan Zamir, CFO Yonah Lloyd, CCO & VP IR May 8, 2025 Make additive work for you Conference Call and Webcast Link US Toll-Free Dial-In 1-877-407-0619 International Dial-In Live Webcast and Replay +1-412-902-1012 Forward -Looking Statements Cautionary Statement Regarding Forward - Looking Statements The statements in this slide presentation regarding Stratasys' strategy, and the statements regarding its projected future financial performance, including the financia ...

Financial Performance - Company reported record first quarter revenue of $222.3 million, up 15.4% year-over-year, driven by double-digit organic growth in both residential and multi-family/commercial projects [1][6] - Single-family residential revenue increased to a first quarter record of $88.9 million, up 21.6% year-over-year [1][6] - Gross margin improved to 43.9%, up 510 basis points year-over-year [1][7] - Net income was $42.2 million, or $0.90 per diluted share, compared to $29.7 million, or $0.63 per diluted share, in the prior year quarter [1][9] - Adjusted net income was $43.1 million, or $0.92 per diluted share, compared to $30.9 million, or $0.66 per diluted share, in the prior year quarter [1][10] - Adjusted EBITDA was $70.2 million, up 37.5% year-over-year, representing 31.6% of total revenues [1][11] Cash Position and Capital Allocation - Company ended the first quarter with an all-time high cash position of $157.3 million and total liquidity of approximately $330 million [2][14] - Strong free cash flow of $28.8 million was generated during the quarter [1] - Company returned $7.0 million in cash dividends to shareholders [12][13] Strategic Developments - Company expanded its backlog by 24.9% year-over-year to a record $1.14 billion [2] - In April 2025, the company acquired Continental Glass Systems for approximately $30 million, enhancing its U.S. manufacturing capabilities [2][15] - Company is launching a feasibility analysis to develop automated manufacturing capabilities in the U.S. over the coming years [2] Market Outlook - Company updated its full year 2025 revenue guidance to a range of $960 million to $1.02 billion, representing growth of approximately 11% at the midpoint [2][17] - Adjusted EBITDA outlook narrowed to a range of $305 million to $330 million, representing growth of approximately 15% at the midpoint [2][17] - Company anticipates a full year 2025 impact of approximately $25 million associated with higher input costs and tariffs, which it expects to mitigate through pricing strategies and supply chain adjustments [2][17]

-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, today announce ...

Core Viewpoint - Alvotech intends to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm to broaden its investor base and enhance visibility among Nordic and European institutional investors following the acquisition of Xbrane Biopharma AB's R&D operations [2][3][8] Offering Details - The Offering will be directed solely into Sweden during an application period from May 9–16, 2025, with a maximum price of SEK 90 per SDR [6][12] - The gross proceeds are estimated to be approximately SEK 30 million, with 441,600 SDRs offered, each representing one Share [6][12] - The first day of trading on Nasdaq Stockholm is expected to be May 19, 2025 [6][12] Strategic Importance - The acquisition of Xbrane's R&D operations is a strategic priority to enhance Alvotech's R&D capabilities and establish a strong presence in the Swedish life-science sector [5][8] - The integration of Xbrane's workforce will expand Alvotech's scientific and innovation capabilities, allowing access to a broader talent pool [5][8] Market Positioning - The listing on Nasdaq Stockholm is expected to strengthen Alvotech's recognition in Nordic and European markets, improving access to regional capital and attracting a broader base of institutional and retail investors [3][8] - Alvotech aims to be a global leader in the biosimilar space, with a current pipeline that includes nine disclosed biosimilar candidates targeting various diseases [13][14] Investor Engagement - A free conversion period will be offered to existing shareholders to convert their Shares into SDRs, with conversion fees covered by Alvotech for one year from the first trading day [9][10] - A prospectus detailing the Offering has been published and is available on Alvotech's website and other financial platforms [10][11]